Immune landscape and heterogeneity of cervical squamous cell carcinoma and adenocarcinoma
Despite the differences in disease outcomes and pathological features between cervical squamous cell carcinoma (CSCC) and adenocarcinoma (ADC), the molecular characteristics in immune heterogeneity of the tumor microenvironment remain unclear. Here, we explored the immune landscape and heterogeneity between CSCC and ADC. Gene expression and clinical characteristics of cervical carcinoma from The Cancer Genome Atlas (TCGA) were downloaded. Differentially expressed genes (DEGs), immune cell infiltration, and pathway enrichment analyses were used to explore the immune landscape and heterogeneity between CSCC and ADC. Furthermore, distinct immune signatures between CSCC and ADC were validated based on clinical samples. In total, 4,132 upregulated DEGs and 2,307 down-regulated DEGs were identified between CSCC and ADC, with enrichments in immune related-pathways in CSCC. In addition, 54 hub DEGs correlated with patients' prognosis and immunocytes infiltration were identified. The CSCC patients had a higher ImmuneScore and more abundant immunocytes infiltration compared to ADC patients, as validated by immunohistochemistry (IHC) and multicolor immunofluorescence (mIF) analyses of collected samples. Furthermore, CSCC displayed higher inhibitory immune checkpoints expression, tumor mutation burden (TMB), and microsatellite instability (MSI) compared to ADC, which indicated CSCC patients were more likely to benefit from immunotherapy. In summary, our results revealed the huge immune heterogeneity between CSCC and ADC, and provided guidance for immunotherapy selection for different pathological types of cervical cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Aging - 16(2024), 1 vom: 10. Jan., Seite 568-592 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Binghan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADC |
|---|
| Anmerkungen: |
Date Completed 23.01.2024 Date Revised 28.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.18632/aging.205397 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366968890 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366968890 | ||
| 003 | DE-627 | ||
| 005 | 20240128231933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/aging.205397 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1273.xml |
| 035 | |a (DE-627)NLM366968890 | ||
| 035 | |a (NLM)38206304 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Binghan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune landscape and heterogeneity of cervical squamous cell carcinoma and adenocarcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2024 | ||
| 500 | |a Date Revised 28.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Despite the differences in disease outcomes and pathological features between cervical squamous cell carcinoma (CSCC) and adenocarcinoma (ADC), the molecular characteristics in immune heterogeneity of the tumor microenvironment remain unclear. Here, we explored the immune landscape and heterogeneity between CSCC and ADC. Gene expression and clinical characteristics of cervical carcinoma from The Cancer Genome Atlas (TCGA) were downloaded. Differentially expressed genes (DEGs), immune cell infiltration, and pathway enrichment analyses were used to explore the immune landscape and heterogeneity between CSCC and ADC. Furthermore, distinct immune signatures between CSCC and ADC were validated based on clinical samples. In total, 4,132 upregulated DEGs and 2,307 down-regulated DEGs were identified between CSCC and ADC, with enrichments in immune related-pathways in CSCC. In addition, 54 hub DEGs correlated with patients' prognosis and immunocytes infiltration were identified. The CSCC patients had a higher ImmuneScore and more abundant immunocytes infiltration compared to ADC patients, as validated by immunohistochemistry (IHC) and multicolor immunofluorescence (mIF) analyses of collected samples. Furthermore, CSCC displayed higher inhibitory immune checkpoints expression, tumor mutation burden (TMB), and microsatellite instability (MSI) compared to ADC, which indicated CSCC patients were more likely to benefit from immunotherapy. In summary, our results revealed the huge immune heterogeneity between CSCC and ADC, and provided guidance for immunotherapy selection for different pathological types of cervical cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADC | |
| 650 | 4 | |a CSCC | |
| 650 | 4 | |a cervical cancer | |
| 650 | 4 | |a immune heterogeneity | |
| 650 | 4 | |a immunotherapy | |
| 700 | 1 | |a Xu, Yashi |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Bai |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Xiaole |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Shitong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiaxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lingfang |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Miaochun |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Wencheng |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Canhui |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Li |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Aging |d 2008 |g 16(2024), 1 vom: 10. Jan., Seite 568-592 |w (DE-627)NLM192249398 |x 1945-4589 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:1 |g day:10 |g month:01 |g pages:568-592 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/aging.205397 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 1 |b 10 |c 01 |h 568-592 | ||